Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer

The purpose of the study is to evaluate the use of a circulating tumor DNA (ctDNA) assay, ie, a "liquid biopsy," as a tool to identify triple-negative breast cancer (TNBC) patients who will or will not experience benefit from treatment with capecitabine. Participants will be monitored for changes in ctDNA in the blood over time received during capecitabine treatment. Results of ctDNA analysis will be correlated to genetic characteristics of individual tumors. This may inform future clinical trials in which patients could receive a different treatment than capecitabine to reduce their risk of breast cancer relapse.

NCT Number	NCT04768426
Lead Sponsor	Stanford University
Conditions	Triple Negative Breast Cancer, Breast Cancer
Enrollment	40 participants
Start Date	2021-02-03
Primary Completion	2026-11 (estimated)
Study Completion	2031-07 (estimated)
Updated on ClinicalTrials.gov	2026-08-12